Differential effects of intrastriatally infused fully and endcap phosphorothioate antisense oligonucleotides on morphology, histochemistry and prodynorphin expression in rat brain

Molecular Brain Research

Volumn 75, Issue 1, 2000, Pages 25-45

  Broberger, C ^a   Nylander, I ^b   Geijer, T ^c   Terenius, L ^a   Hokfelt T ^a   Georgieva, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Dept of Pharmaceutical Biosciences   (Sweden)

^c Ctr for Suicide Res and Prevention   (Sweden)

Author keywords

Antisense oligonucleotide; Dynorphin; Immunohistochemistry; Neuropeptide; Radioimmunoassay; Toxicity

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; FLUORESCEIN ISOTHIOCYANATE; NEUROPEPTIDE Y; PRODYNORPHIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN TISSUE; CELL INFILTRATION; CHOLINERGIC NERVE; CONTROLLED STUDY; CORPUS STRIATUM; HISTOCHEMISTRY; INTERNEURON; MALE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; RAT; SUBSTANTIA NIGRA;

ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CORPUS STRIATUM; DYNORPHINS; ENKEPHALINS; GENE EXPRESSION REGULATION; INFUSIONS, PARENTERAL; NEURONS; NEUROPEPTIDE Y; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTEIN PRECURSORS; RATS; RNA, MESSENGER; THIONUCLEOTIDES; TRANSCRIPTION, GENETIC; TYROSINE 3-MONOOXYGENASE;

EID: 0033963367     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00276-4     Document Type: Article

References (58)

1. Akhtar S., Kole R., Juliano R.L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1991;1793-1801.
2. Allen Y.S., Adrian T.E., Allen J.M., Tatemoto K., Crow T.J., Bloom S.R., Polak J.M. Neuropeptide Y distribution in the rat brain. Science. 221:1983;877-879.
3. Andén N.E., Dahlström A., Fuxe K., Larsson K., Olson L., Ungerstedt U. Ascending monoamine neurons to the telencephalon and diencephalon. Acta Physiol. Scand. 67:1966;313-326.
4. Andersson P.-B., Perry V.H., Gordon S. The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neuroscience. 48:1992;169-186.
5. Andersson P.-B., Perry V.H., Gordon S. Intracerebral injection of proinflammatory cytokines of leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J. Exp. Med. 176:1992;255-259.
6. Bergström L., Christensson I., Folkesson R., Stenström B., Terenius L. An ion-exchange chromatography and radioimmunoassay procedure for measuring opioid peptides and substance P. Life Sci. 33:1983;1613-1619.
7. Brenner T. Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J. Neurol. Sci. 122:1994;210-213.
8. Campbell J.M., Bacon T.A., Wickstrom E. Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods. 20:1990;259-267.
9. Chiasson B.J., Armstrong J.N., Hooper M.L., Murphy P.R., Robertson H.A. The application of antisense oligonucleotide technology to the brain: some pitfalls. Cell. Mol. Neurobiol. 14:1994;507-521.
10. Chiasson B.J., Hooper M.L., Murphy P.R., Robertson H.A. Antisense oligonucleotide eliminates in vivo expression of c-fos in mammalian brain. Eur. J. Pharmacol. 227:1992;451-453.
11. Chronwall B.M., DiMaggio D.A., Massari V.J., Pickel V.M., Ruggiero D.A., O'Donohue T.L. The anatomy of neuropeptide Y-containing neurons in rat brain. Neuroscience. 15:1985;1159-1181.
12. Condon T.P., Bennett C.F. Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells. J. Biol. Chem. 271:1996;30398-30403.
13. A.H. Coons, Fluorescent antibody methods, in: J.F. Danielli (Ed.), General Cytochemical Methods, Academic Press, New York, 1958, pp. 399-422.
14. Crooke S.T., Bennett C.F. Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36:1996;107-129.
15. Dash P., Lotan I., Knapp M., Kande E.R., Goelet P. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. U. S. A. 84:1987;7896-7900.
16. R. Day, K.A. Trujillo, H. Akil, Prodynorphin biosynthesis and posttranslational processing, in: G.V.R. Born, P. Cuatrecasas, H. Herken (Eds.), Handbook of Experimental Pharmacology, 1995.
17. de Quidt M.E., Emson P.C. Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system: II. Immunohistochemical analysis. Neuroscience. 18:1986;545-618.
18. J.H. Fallon, P. Ciofi, Dynorphin-containing neurons, in: A. Björklund, T. Hökfelt, M.J. Kuhar (Eds.), Handbook of Chemical Neuroanatomy, Vol. 9. Neuropeptides in the CNS, Elsevier, Amsterdam, 1990, pp. 1-130.
19. Galbraith W.M., Hobson W.C., Giclas P.C., Schechter P.J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. 4:1994;201-206.
20. Georgieva J., Heilig M., Nylander I., Herrera-Marschitz M., Terenius L. In vivo antisense inhibition of prodynorphin expression in rat striatum: dose-dependence and sequence specificity. Neurosci. Lett. 192:1995;69-71.
21. Grzanna R., Dubin J.R., Dent G.W., Ji Z., Zhang W., Peng Ho S., Hartig P.R. Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects. Mol. Brain Res. 63:1998;35-52.
22. Hebb M.O., Robertson H.A. End-capped antisense oligodeoxynucleotides effectively inhibit gene expression in vivo and offer a low-toxicity alternative to fully modified phosphorothioate oligodeoxynucleotides. Mol. Brain Res. 47:1997;223-228.
23. Hebb M.O., Robertson H.A. Coordinate suppression of striatal ngfi-a and c-fos produces locomotor asymmetry and up-regulation of IEGs in the globus pallidus. Mol. Brain Res. 48:1997;97-106.
24. Ji R.R., Zhang Q., Bedecs K., Arvidsson J., Zhang X., Xu X.J., Wiesenfeld-Hallin Z., Bartfai T., Hökfelt T. Galanin antisense oligonucleotides reduce galanin levels in dorsal root ganglia and induce autotomy in rats after axotomy. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12540-12543.
25. Johnson G.D., Nogueira Araujo G.M. A simple method of reducing the fading of immunofluorescence during microscopy. J. Immunol. Methods. 43:1981;349-350.
26. Koelle G.B. The histochemical localization of cholinesterases in the central nervous system of the rat. J. Comp. Neurol. 100:1954;211-235.
27. Krieg A.M., Yi A.-K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 374:1995;546-549.
28. Lambracht-Hall M., Dimitriadou V., Theoharides T.C. Migration of mast cells in the developing rat brain. Dev. Brain Res. 56:1990;151-159.
29. 2C-adrenoceptors in rat striatum following antisense oligodeoxynucleotide infusion. Mol. Brain Res. 47:1997;267-274.
30. Markey K.A., Kondo S., Shenkman L., Goldstein M. Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line. Mol. Pharmacol. 17:1980;79-85.
31. Marsh D., Grassi J., Vigny M., Massoulié J. An immunological study of rat acetylcholinesterase: comparison with acetylcholinesterases from other vertebrates. J. Neurochem. 43:1984;204-213.
32. 67 mRNAs modulates reproductive behavior in the female rat. Brain Res. 636:1994;209-220.
33. Nylander I., Vlaskovska M., Terenius L. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology. 118:1995;391-400.
34. Ogawa S., Brown H.E., Okano H.J., Pfaff D.W. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul. Pept. 59:1995;143-149.
35. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, San Diego, 1986.
36. Perez J.R., Li Y., Stein C.A., Majumder S., van Oorschot A., Narayanan R. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5957-5961.
37. Platt J.L., Michael A.F. Retardation of fading and enhancement of intensity of immunofluorescence by p-phenylenediamine. J. Histochem. Cytochem. 31:1983;840-842.
38. Pollio G., Xue P., Zanisi M., Nicolin A., Maggi A. Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats. Mol. Brain Res. 19:1993;135-139.
39. Shaw D.R., Rustagi P.K., Kandimalla E.R., Manning A.N., Jiang Z., Agrawal S. Effects of synthetic oligonucleotides on human complement and coagulation. Biochem. Pharmacol. 53:1997;1123-1132.
40. Smetsers T.F.C.M., van de Locht L.T.F., Pennings A.H.M., Wessels H.M.C., de Witte T.M., Mensink E.J.B.M. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular Bcr-Abl protein levels. Leukemia. 9:1995;118-130.
41. Sommer W., Cui X., Erdmann B., Wiklund L., Bricca G., Heilig M., Fuxe K. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev. 8:1998;75-85.
42. Sommer W., Rimondini R., O'Connor W., Hansson A.C., Ungerstedt U., Fuxe K. Intrastriatally injected c-fos antisense oligonucleotide interferes with stratonigral but not striatopallidal γ-aminobutyric acid transmission in the conscious rat. Proc. Natl. Acad. Sci. U. S. A. 93:1996;14134-14139.
43. Standifer K.M., Chien C.C., Wahlestedt C., Brown G.P., Pasternak G.W. Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor. Neuron. 12:1994;805-810.
44. Stein C.A. Does antisense exist? Nat. Med. 1:1995;1119-1121.
45. 3 autoreceptors on neurostriatal neurons analyzed by antisense knockdown in vivo. J. Neurosci. 17:1997;2519-2530.
46. Trujillo K.A., Bronstein D.M., Sanchez I.O., Akil H. Effects of chronic opiate and opioid antagonist treatment on striatal opioid peptides. Brain Res. 698:1995;69-78.
47. 5) enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport. 5:1994;2601-2605.
48. Vincent S., Hökfelt T., Christensson I., Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur. J. Pharmacol. 85:1982;251-252.
49. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol. Sci. 15:1994;42-46.
50. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature. 363:1993;260-263.
51. Walder R.Y., Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5011-5015.
52. Yaswen P., Stampfer M.R., Ghosh K., Cohen J.S. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 3:1993;67-77.
53. Zamboni I., De Martino C. Buffered picric acid formaldehyde. A new rapid fixative for electron microscopy. J. Cell Biol. 35:1967;148A.
54. Zamecnik P., Aghjanian J., Zamecnik M., Goodchild J., Witman G. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3156-3160.
55. Zamecnik P.C., Stephenson M.L. Inhibition of Rous sarcoma virus, replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75:1978;280-284.
56. Zhang R., Iyer R.P., Yu D., Tan W., Zhang X., Lu Z., Zhao H., Agrawal S. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration. J. Pharmacol. Exp. Ther. 278:1996;971-979.
57. Zhang R., Yan J., Shahinian H., Amin G., Lu Z., Liu T., Saag M.S., Jiang Z., Temsamani J., Martin R.R.E.A. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. 58:1995;44-53.
58. Zhou L.W., Zhang S.P., Qin Z.H., Weiss B. In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum. J. Pharmacol. Exp. Ther. 268:1994;1015-1023.